Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Queensland Health
Cantor Fitzgerald

Generated: April 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,393,529

« Back to Dashboard

Summary for Patent: 5,393,529
Title: Estrogen-containing active substance plaster
Abstract:The present invention relates to active substance plasters for the controlled release of active substances to the skin consisting of a backing layer, an adhesive film connected therewith which film is water-soluble and consists of pressure-sensitive adhesive which comprises water-swellable polymers and in which the active substance is at least partially soluble, and of a removable protective layer covering the adhesive film, in which plasters the pressure-sensitive adhesive is based on homo and/or copolymers with at least one derivative of the acrylic or methacrylic acid, and which comprise as active substances, partially or completely dissolved in the adhesive, at a concentration of 0.5 to 10.0%-wt estrogens and their pharmaceutically acceptable derivatives alone or in combination with gestagens.
Inventor(s): Hoffmann; Hans-Rainer (Neuwied, DE), Klein; Robert P. (Neuwied, DE), Meconi; Reinhold (Neuwied, DE), Cordes; Gunter (Leichingen, DE), Wolff; Hans M. (Monheim, DE)
Assignee: LTS Lohmann Therapie-Systeme GmbH & Co. KG (Neuweid, DE) Schwarz Pharma AG (Monheim, DE)
Application Number:08/074,698
Patent Claims: 1. In a plaster for the controlled release of an estrogen to the skin and comprising

A) an impermeable backing or covering layer,

B) a reservoir layer adjacent to, and in close contact with said backing or covering layer, said reservoir layer comprising a water-insoluble pressure-sensitive adhesive polymer layer containing the estrogen in a concentration of about 0.5 to 10 by weight, in combination with at least one water-swellable polymer in 0.01 to 10% wt, and

C) a protective layer covering and adhering to said adhesive polymer layer and removable therefrom for the use of said transdemal drug patch, the improvement wherein the pressure-sensitive adhesive polymer of B is a polymer of acrylic or methacrylic acid or an ester thereof, and contains a 0.1 to 20%-wt of at least one substance delaying or preventing the crystallization of the active substance,

the water-swellable polymer being selected from the group consisting of galactomannans, cellulose products, tragacanth, polyglycosides, polyvinylpyrrolidones, finely pulverized polyamides, water-soluble polyacrylamide, carboxyvinyl polymers, agar, copolymers of methylvinyl ether and maleic acid anhydride, guar gum, hydroxypropyl guar gum or guar flour, gum arabic, dextrin and dextran, polysaccharide gum, hydroxymethylpropyl cellulose, pectin and pectinamide, and

the crystallization delaying or preventing substance being selected from the group consisting of phthalic acid esters, adipic acid esters, monoglycerides, diglycerides, and triglycerides, ester of higher fatty acids, long-chain alcohols, nonylphenol, octylphenol, fatty acids, sorbitol, mannitol, non-ionogenic surfactants, polyoxyethylene alkyl esters, castor oil, sitosterine and polyvinylpyrrolidone.

2. A plaster according to claim 1, wherein the polymer of B is cross-linkable.

3. A plaster according to claim 1, wherein the polymer of B is a solvent-based pressure-sensitive adhesive.

4. A plaster according to claim 1, wherein the polymer of B is a dispersion-based pressure-sensitive adhesive.

5. A plaster according to claim 1, wherein the polymer of C is a hot-melt-pressure-sensitive adhesive.

6. A plaster according to claim 1, wherein the pressure-sensitive adhesive comprises at least one tackifying resin in an amount of 0.5 to 50%-wt.

7. A plaster according to claim 1, wherein the therapeutic substance-containing adhesive film has a thickness of 0.01 to 0.3 mm.

8. A plaster according to claim 1, wherein the additionally water-swellable polymer of layer C is selected from the group consisting of galactomannan, microcrystalline cellulose and tragacanth.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.